This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Carvedilol, Kredex, Eucardic
Description: Coreg (Carvedilol) is a nonselective ß-adrenergic blocking agent with a1-blocking activity. Coreg lowers cardiac output and lowers blood pressure without worsening blood sugar or cholesterol levels.
Deal Structure: Coreg CR tablets are the controlled-release formulations of Coreg.
In May 1998, Hoffmann-La Roche commenced co-promotion with SmithKline Beecham (SB) of Coreg. Roche will co-promote Coreg as part of its acquisition of Boehringer Mannheim.
In August 2000, SB paid Roche $400 million in cash for exclusive rights, in the United States and Canada, for Coreg.
Pink Sheet GlaxoSmithKline Coreg expands indications
Additional information available to subscribers only: